REMD Biotherapeutics, Inc., together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd, announced they have completed enrollment and have top-line results in a Phase II study of volagidemab (REMD-477) in patients with type 1 diabetes. The study is a randomized, placebo-controlled, double-blind study to evaluate the safety, efficacy, and pharmacodynamics of volagidemab at 35 mg and 70 mg in patients with type 1 diabetes who are currently receiving insulin treatment.
[REMD Biotherapeutics, Inc. (Business Wire, Inc.)]
0